- Home
- EAD vs BNTC Comparison
EAD vs BNTC Comparison
Compare EAD & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EAD | BNTC |
|---|---|---|
| Founded | 2003 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.8M | 365.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EAD | BNTC |
|---|---|---|
| Price | $6.89 | $13.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $26.00 |
| AVG Volume (30 Days) | 178.9K | ★ 276.5K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 8.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.69 | $9.49 |
| 52 Week High | $6.81 | $17.15 |
Technical Indicators
Market Signals| Indicator | EAD | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 54.87 | 51.20 |
| Support Level | $6.84 | $11.54 |
| Resistance Level | $6.90 | $13.17 |
| Average True Range (ATR) | 0.06 | 0.84 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 88.00 | 84.44 |
Price Performance
Historical ComparisonAbout EAD Allspring Income Opportunities Fund
Allspring Income Opportunities Fund is a diversified closed-end management investment company. Its products and services are mutual funds, closed-end funds, managed accounts services, and variable trust funds. The fund's objective is a high level of current income and capital appreciation. Its portfolio of investments is Commercial services, healthcare services, Food, Pharmaceuticals, Energy, Oil & gas, Pipelines, Diversified financial services, and Others.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.